Nothing Special   »   [go: up one dir, main page]

PE20210552A1 - Anticuerpos anti-transtiretina - Google Patents

Anticuerpos anti-transtiretina

Info

Publication number
PE20210552A1
PE20210552A1 PE2020000481A PE2020000481A PE20210552A1 PE 20210552 A1 PE20210552 A1 PE 20210552A1 PE 2020000481 A PE2020000481 A PE 2020000481A PE 2020000481 A PE2020000481 A PE 2020000481A PE 20210552 A1 PE20210552 A1 PE 20210552A1
Authority
PE
Peru
Prior art keywords
antibody
transthyretin
refers
monoclonal antibody
antibodies
Prior art date
Application number
PE2020000481A
Other languages
English (en)
Inventor
Joshua Reginald Salmans
Svetlana Alexander
Robin Barbour
Tarlochan S Nijjar
Jeffrey N Higaki
Original Assignee
Prothena Biosciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prothena Biosciences Ltd filed Critical Prothena Biosciences Ltd
Publication of PE20210552A1 publication Critical patent/PE20210552A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/60Salicylic acid; Derivatives thereof
    • A61K31/603Salicylic acid; Derivatives thereof having further aromatic rings, e.g. diflunisal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/65Tetracyclines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/713Double-stranded nucleic acids or oligonucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567Framework region [FR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Referido a un anticuerpo monoclonal aislado que compite por la union a transtiretina (TTR) humana con el anticuerpo monoclonal 18C5. Los ejemplos de dichos anticuerpos se unen a un epitope dentro de los residuos aminoacidos 101-109 de la region madura de la SEQ ID NO: 26. Tambien se refiere a un acido nucleico que codifica la cadena pesada y/o la cadena liviana de dicho anticuerpo, un vector de expresion recombinante, una celula hospedadora transformada con el vector, un metodo para humanizar un anticuerpo, un metodo para producir un anticuerpo humanizado, un metodo para detectar la presencia o ausencia de depositos de transtiretina y un metodo de diagnostico de amiloidosis mediada por transtiretina.
PE2020000481A 2017-10-06 2018-10-05 Anticuerpos anti-transtiretina PE20210552A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762569436P 2017-10-06 2017-10-06
US201762598965P 2017-12-14 2017-12-14
PCT/US2018/054720 WO2019071205A1 (en) 2017-10-06 2018-10-05 ANTI-TRANSTHYRETIN ANTIBODY

Publications (1)

Publication Number Publication Date
PE20210552A1 true PE20210552A1 (es) 2021-03-17

Family

ID=65994817

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2020000481A PE20210552A1 (es) 2017-10-06 2018-10-05 Anticuerpos anti-transtiretina

Country Status (15)

Country Link
US (1) US11267877B2 (es)
EP (1) EP3691447A4 (es)
JP (1) JP7357609B2 (es)
KR (1) KR20200074956A (es)
CN (1) CN111315213B (es)
AU (1) AU2018345806A1 (es)
BR (1) BR112020006434A2 (es)
CA (1) CA3077361A1 (es)
CU (1) CU20200021A7 (es)
MX (1) MX2020003041A (es)
PE (1) PE20210552A1 (es)
SA (1) SA520411703B1 (es)
SG (1) SG11202002489YA (es)
WO (1) WO2019071205A1 (es)
ZA (1) ZA202002141B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10633433B2 (en) 2015-01-28 2020-04-28 Prothena Biosciences Limited Anti-transthyretin antibodies
US10464999B2 (en) 2015-01-28 2019-11-05 Prothena Biosciences Limited Anti-transthyretin antibodies
US9879080B2 (en) 2015-01-28 2018-01-30 Prothena Biosciences Limited Anti-transthyretin antibodies
PE20210552A1 (es) 2017-10-06 2021-03-17 Prothena Biosciences Ltd Anticuerpos anti-transtiretina
US11873332B2 (en) 2017-11-29 2024-01-16 Novo Nordisk A/S Lyophilized formulation of a monoclonal antibody against transthyretin
KR20230009950A (ko) 2020-05-12 2023-01-17 뉴리뮨 아게 Ttr 아밀로이드증에 대한 조합 치료법
WO2023099788A1 (en) 2021-12-03 2023-06-08 Neurimmune Ag Novel potency assay for antibody-based drugs and useful means therefor
TW202346340A (zh) * 2022-04-20 2023-12-01 美商聖堤生物科技股份有限公司 抗原結合域及其使用方法
WO2024121156A1 (en) 2022-12-05 2024-06-13 Neurimmune Ag Cyclic compounds and their use in assays for detecting antibodies

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
AU2001253158A1 (en) 2000-04-05 2001-10-23 University Of Tennessee Research Corporation Methods of investigating, diagnosing, and treating amyloidosis
US8871447B2 (en) 2002-09-12 2014-10-28 The Regents Of The University Of California Immunogens and corresponding antibodies specific for high molecular weight aggregation intermediates common to amyloids formed from proteins of differing sequence
WO2010011999A2 (en) 2008-07-25 2010-01-28 The Regents Of The University Of California Methods and compositions for eliciting an amyloid-selective immune response
WO2010012004A2 (en) 2008-07-25 2010-01-28 The Regents Of The University Of California Monoclonal antibodies specific for pathological amyoid aggregates common to amyloids formed from proteins of differing sequence
US20110200609A1 (en) 2002-09-12 2011-08-18 The Regents Of The University Of California Monoclonal antibodies specific for pathological amyloid aggregates common to amyloids formed from proteins of differing sequence
EP1660533A4 (en) 2003-09-12 2009-10-21 Univ California SPECIFIC MONOCLONAL ANTIBODIES MADE FROM PROTEINS OF DIFFERENT SEQUENCES FOR HIGHLY MOLECULAR AGGREGATIVE INTERMEDIATE PRODUCTS OF AMYLOIDS
CA2604423A1 (en) * 2005-04-13 2006-10-19 Garvan Institute Of Medical Research Modified animal lacking functional pyy gene, monoclonal antibodies that bind pyy isoforms and uses therefor
DK2514823T3 (en) 2006-03-03 2018-07-23 Promis Neurosciences Inc Methods and compositions for treating and detecting failed SOD1-mediated diseases
US8232066B2 (en) 2006-07-03 2012-07-31 The Johns Hopkins University Peptide antibody depletion and its application to mass spectrometry sample preparation
EP2548647B1 (en) 2006-10-20 2018-08-15 CLONDIAG GmbH Assay devices and methods for the detection of analytes
WO2010030203A1 (en) 2008-09-09 2010-03-18 Biocodex - Incubação De Empresas De Ciências Da Vida, S.A. Monoclonal antibody to human amyloidogenic and modified forms of transthyretin and its use in the detection and treatment of fap and pathologies presenting modified ttr
AU2009301580B2 (en) 2008-10-06 2015-11-26 The University Of British Columbia Methods and systems for predicting misfolded protein epitopes
JP2010195710A (ja) 2009-02-25 2010-09-09 Kumamoto Univ アミロイド線維形成抑制剤及びその利用
AU2010220781A1 (en) 2009-03-02 2011-10-06 The University Of British Columbia Antibodies and epitopes specific to misfolded prion protein
TWI667346B (zh) 2010-03-30 2019-08-01 中外製藥股份有限公司 促進抗原消失之具有經修飾的FcRn親和力之抗體
FI20115165A0 (fi) * 2011-02-21 2011-02-21 Polysackaridforskning I Uppsala Ab Terapeuttisia ja diagnostisia menetelmiä
KR102147548B1 (ko) 2011-02-25 2020-08-24 추가이 세이야쿠 가부시키가이샤 FcγRIIb 특이적 Fc 항체
EP2698431B1 (en) 2011-03-30 2020-09-09 Chugai Seiyaku Kabushiki Kaisha Retention of antigen-binding molecules in blood plasma and method for modifying immunogenicity
TW201817744A (zh) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之FcRn結合域的治療性抗原結合分子
ES2856272T3 (es) 2012-05-30 2021-09-27 Chugai Pharmaceutical Co Ltd Molécula de unión a antígenos para eliminar antígenos agregados
US9534048B2 (en) * 2012-08-24 2017-01-03 University Health Network Antibodies to TTR and methods of use
UA118441C2 (uk) 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
US9790269B2 (en) 2013-02-08 2017-10-17 Misfolding Diagnostics, Inc. Transthyretin antibodies and uses thereof
WO2014142334A1 (ja) * 2013-03-12 2014-09-18 国立大学法人名古屋大学 植物の光合成および生産量を増加させる方法
US20160168235A1 (en) 2013-07-19 2016-06-16 Board Of Regents Of The University Of Texas System Transthyretin amyloid-selective and polyreactive catabodies
LT3083681T (lt) * 2013-12-20 2020-11-25 Neurimmune Holding Ag Transtiretino (ttr) amiloidozės terapija antikūnų pagrindu ir jai skirti iš žmogaus organizmo gauti antikūnai
JP6517156B2 (ja) 2014-01-29 2019-05-22 Kmバイオロジクス株式会社 抗トランスサイレチンヒト抗体
JP6818268B2 (ja) * 2014-01-29 2021-01-20 Kmバイオロジクス株式会社 抗トランスサイレチンヒト化抗体
PL3185957T3 (pl) 2014-08-29 2022-11-14 Alnylam Pharmaceuticals, Inc. Patisiran do zastosowania w leczeniu amyloidozy związanej z transtyretyną
TWI806150B (zh) 2014-11-07 2023-06-21 瑞士商諾華公司 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物
TWI781507B (zh) * 2015-01-28 2022-10-21 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體
TWI711631B (zh) * 2015-01-28 2020-12-01 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體
TWI786505B (zh) 2015-01-28 2022-12-11 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體
US10464999B2 (en) 2015-01-28 2019-11-05 Prothena Biosciences Limited Anti-transthyretin antibodies
US10633433B2 (en) 2015-01-28 2020-04-28 Prothena Biosciences Limited Anti-transthyretin antibodies
US9879080B2 (en) 2015-01-28 2018-01-30 Prothena Biosciences Limited Anti-transthyretin antibodies
WO2018007923A2 (en) 2016-07-02 2018-01-11 Prothena Biosciences Limited Anti-transthyretin antibodies
EP3478716A2 (en) 2016-07-02 2019-05-08 Prothena Biosciences Limited Anti-transthyretin antibodies
WO2018007922A2 (en) 2016-07-02 2018-01-11 Prothena Biosciences Limited Anti-transthyretin antibodies
AU2018345807A1 (en) 2017-10-06 2020-03-12 Novo Nordisk A/S Methods of detecting transthyretin
PE20210552A1 (es) 2017-10-06 2021-03-17 Prothena Biosciences Ltd Anticuerpos anti-transtiretina
US11873332B2 (en) 2017-11-29 2024-01-16 Novo Nordisk A/S Lyophilized formulation of a monoclonal antibody against transthyretin
WO2021168156A1 (en) 2020-02-20 2021-08-26 Prothena Biosciences Limited Monitoring transthyretin amyloidosis

Also Published As

Publication number Publication date
JP2020536532A (ja) 2020-12-17
KR20200074956A (ko) 2020-06-25
SA520411703B1 (ar) 2024-04-28
JP7357609B2 (ja) 2023-10-06
EP3691447A1 (en) 2020-08-12
ZA202002141B (en) 2023-01-25
WO2019071205A1 (en) 2019-04-11
CA3077361A1 (en) 2019-04-11
CN111315213B (zh) 2023-09-12
CN111315213A (zh) 2020-06-19
SG11202002489YA (en) 2020-04-29
BR112020006434A2 (pt) 2020-11-03
EP3691447A4 (en) 2021-08-11
MX2020003041A (es) 2020-10-05
US20200331992A1 (en) 2020-10-22
US11267877B2 (en) 2022-03-08
AU2018345806A1 (en) 2020-03-12
CU20200021A7 (es) 2021-01-12

Similar Documents

Publication Publication Date Title
PE20210552A1 (es) Anticuerpos anti-transtiretina
AR108377A1 (es) Proteínas de unión biespecíficas y sus usos
PE20211291A1 (es) Anticuerpos anti-ox40 y metodos de uso
MX2023001791A (es) Anticuerpos dirigidos contra receptor de interleucina 36 (il-36r).
PE20181089A1 (es) Anticuerpos anti-cd19 humano con alta afinidad
PE20181044A1 (es) Anticuerpos anti-pd-1 y composiciones
PE20181046A1 (es) Anticuerpos anti-tigit y metodos de uso
AR101846A1 (es) Anticuerpos anti-cll-1 e inmunoconjugados
PE20211605A1 (es) ANTICUERPOS ANTI-avß8 Y COMPOSICIONES Y USOS DE LOS MISMOS
EA201792184A1 (ru) Антитела, направленные против т-клеточного иммуноглобулина и белка муцина 3 (tim-3)
CU20180136A7 (es) Anticuerpos monoclonales aislados que compiten por la union a tau con el anticuerpo 16g7
PE20141162A1 (es) Anticuerpos anti-il-23
AR084141A1 (es) Anticuerpos neutralizadores anti-ccl20
MX2017004117A (es) Moleculas de enlace, especialmente anticuerpos, enlazadas a l1cam(cd171).
CL2021000942A1 (es) Anticuerpos anti-npr1 y usos relacionados.
NI201800113A (es) Anticuerpos anti-basigin humanizados y uso de los mismos.
CO2017004753A2 (es) Anticuerpos que se unen a ccr6
CO2021014153A2 (es) Anticuerpo monoclonal que se une específicamente a gitr
MX2019002178A (es) Peptidos de fusion con antigenos enlazados a fragmentos cortos de cadena invariante (cd74).
PE20191319A1 (es) Anticuerpos novedosos contra el factor xi y sus usos
PE20181051A1 (es) Anticuerpo anti-epha4
PE20181199A1 (es) Anticuerpos que se unen al receptor cannabinoide 1 (cb1) humano
BR112022005404A2 (pt) Anticorpo monoclonal contra a proteína de ativação de fibroblastos canina que reage de forma cruzada com a proteína de ativação de fibroblastos de camundongo e humana (fap)
PE20190633A1 (es) Anticuerpos anti-gm-csf y usos de los mismos
PE20210019A1 (es) Anticuerpos injertados con peptido natriuretico cerebral